Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Prepaid Assets (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Prepaid Assets for 8 consecutive years, with $848000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Prepaid Assets fell 88.08% to $848000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $848000.0, a 88.08% decrease, with the full-year FY2024 number at $369000.0, down 11.93% from a year prior.
  • Prepaid Assets was $848000.0 for Q3 2025 at Precision Biosciences, up from $427000.0 in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $17.4 million in Q4 2021 to a low of $116000.0 in Q1 2025.
  • A 5-year average of $5.2 million and a median of $5.4 million in 2021 define the central range for Prepaid Assets.
  • Peak YoY movement for Prepaid Assets: skyrocketed 435750.0% in 2021, then tumbled 98.75% in 2025.
  • Precision Biosciences' Prepaid Assets stood at $17.4 million in 2021, then tumbled by 65.44% to $6.0 million in 2022, then tumbled by 93.05% to $419000.0 in 2023, then dropped by 11.93% to $369000.0 in 2024, then skyrocketed by 129.81% to $848000.0 in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Prepaid Assets are $848000.0 (Q3 2025), $427000.0 (Q2 2025), and $116000.0 (Q1 2025).